Rk Pharma Solutions LLC

Rk Pharma Inc.

Jayaraman Kannappan

Ravishanker Kovi

Shivnath Sahebrao Patil

Veerabhadra Rao Bobbili

Rajesh A Patel

Hemant Mande

Govind Ahirrao

George Roby Thomas

Sanjaysinh Fatesinh Thakor

Vamshi Yekkanti

Sandeep Aher

Patel Mitesh Manubhai

Raghu Kasu

Thupalli Ajeykumar Reddy

Dusanapudi Naga Venkata Raghavulu

Srikrishna Apar

Rahul Dixit

Nirmal Chaitanya Indravadanbhai

Shivam Saroj

Chowdari Bhushaiah Talluri

Sai Saisuryanarayana Donthukurthi

Piyush Fadadu

Aditya Khanvilkar

Daxeshkumar Prakashbhai Patel

The present application provides method for producing methylene blue that includes the steps of providing a reaction mixture having one or more methylene blue intermediates; precipitating metal from the reaction mixture; and producing therefrom crude methylene blue. The crude may further be purified, resulting in methylene compounds having low impurities, preferably having a purity greater than about 97%, having Azure B impurity no greater than 2.5%, and/or a total metal content no greater than 77 ppm. Formulations containing such compounds are also provided.

Process for the purification of methylene blue

The present application provides stable ready-to-use injectable formulations of melphalan, methods for preparing storage-stable, ready-to-use injectable formulations that include melphalan, which are easy to administer without need of any reconstitution step and has a desirable solubility, stability, and safety profile. In other embodiments, provided are storage-stable, ready-to-use, injectable liquid parenteral formulations that include melphalan and other pharmaceutically acceptable excipients.

Ready to use injectable formulations of melphalan and processes for preparation thereof

Liquid parenteral formulations are provided that include tigecycline and at least one or more pharmaceutically acceptable excipient or adjuvant, where the formulation is ready to use without additional steps for reconstitution at the time of administration.

Storage-stable ready-to-use formulations of tigecycline

The present application provides improved processes for the synthesis of eribulin intermediate, which generally comprise the steps of: a) De-protecting the eribulin-enone (compound 1) in tetrahydrofuran by using TBAF solution, buffered with imidazole HCl in the presence of molecular sieve and sodium sulphate to get an insitu mixture of eribulin-dione diastereomer at C12 carbon (compound 2). Then ketalization may be performed of eribulin-dione insitu intermediate containing mixture of diastereomer at C12 carbon (compound 2) with PPTS in dichloromethane to yield eribulin-diol (compound 3).

Process for the preparation of eribulin mesylate intermediate

Methods for preparing degarelix acetate are provided that include the steps of providing a suitable resin; deprotecting the resin with a diethylenetriamine solution; reacting sequentially the deprotected resin with different Fmoc protected amino acids; deprotecting the amino acid in each sequence with a diethylenetriamine solution in a stepwise fashion to yield a degarelix crude compound; and purifying the degarelix crude compound to yield pharmaceutically acceptable degarelix acetate. Methods of preparing degarelix acetate-mannitol premix and the resulting degarelix acetate-mannitol premix are also provided.

Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix

A process for the preparation of hydroxocobalamin hydrochloride. More particularly the present application relates to improved process for the preparation of Hydroxocobalamin hydrochloride. In addition the present application also relates to process for the preparation of novel amorphous form. This application particularly relates to a process for the industrial manufacture of hydroxocobalamin hydrochloride from cyanocobalamin. The present application also relates to the improvement in yield with better purity of Hydroxocobalamin hydrochloride.

Process for the preparation of hydroxocobalamin hydrochloride

A stable, ready-to-use injectable solution including thiotepa and one or more pharmaceutically acceptable solvents, co-solvents, and/or solubilizing agents. Formulations retain at least 90% and as high as 99% of the purity of thiotepa as measured by HPLC after storage at 25&#xb0; C./60% RH for a period of 7 days. Certain formulations retain at least 99% of the purity of thiotepa as measured by HPLC after storage for at least six months at 2-8&#xb0; C.

Storage-stable ready-to-use injectable formulations of thiotepa

The present application provides methods for the synthesis of intermediates in the synthesis of Safinamide or a pharmaceutically acceptable salt thereof herein Safinamide Mesylate, that is substantially free of impurities.

Process for the preparation of safinamide mesylate intermediate

Growing community of inventors

Vadodara, India

Jayaraman Kannappan